Next-Generation synthetic cannabinoid therapeutics

Gerne möchte ich hier einen möglicherweise aussichtsreichen Wert vorstellen.

Zynerba gab bekannt, dass die ersten Patienten der Gesellschaft mit einer  Phase 2 der klinischen Studie begonnen haben. Es handelt sich hierbei um eine randomisierte, multizentrische  , Studie für Mehrfachdosis. Hierbei soll das entwickelte ZYN002 Cannabidiol ( CBD) Gel , zur Behandlung von Epilepsie bei Erwachsenen bewertet werden. Patienten mit refraktären fokalen Anfällen bei der Behandlung von Epilepsie , Osteoarthritis (OA) und Fragile -X-Syndrom ( FXS) mti  ZYN002 CBD-Gel (das erste und einzige synthetische CBD) zur transdermalen Verabreichung.

Original Mitteilung/Zitat:"DEVON, Pa., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the first patients have been dosed in the Company’s Phase 2 STAR 1 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial, a randomized, multi-center, multi-dose study to evaluate ZYN002 cannabidiol (CBD) gel in adult epilepsy patients with refractory focal seizures.  ZYN002 CBD gel is the first and only synthetic CBD formulated as a permeation-enhanced gel for transdermal delivery and is in development for the treatment of epilepsy, osteoarthritis (OA) and Fragile X syndrome (FXS)." ENDE Zitat

Source:www.stockwatch.com/News/...160801&symbol=ZYNE&region=U

Zitat:"DEVON, Pa., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the Company will present at Canaccord Genuity’s 36th Annual Growth Conference. The conference will be held August 10 to 11, at the InterContinental Boston. Zynerba Chairman and CEO Armando Anido will present on Wednesday, August 10, at 12:00 pm Eastern Daylight Time." ENDE Zitat

Source:marijuanaindex.com/industry-news-item/?newsId=8433640198110081

Company: zynerba.com/about-us-2/

Zitat:"Zynerba Pharmaceuticals Inc. (ZYNE) was one of the weakest stocks in the healthcare sector of the NYSE and NASDAQ listed companies on August 3, skidding 4.35% to close the day at $8.8 after closing the day prior at $9.2. Throughout the day, shares of ZYNE traded as high as $9.43 and as low as $8.57. Today's decline came with about 181,860 shares changing hands, compared to an average 30-day volume of 202,638 for Zynerba Pharmaceuticals Inc.. The price is currently below the 30-day volume weighted average price of $8.84 for ZYNE. The share depreciation gives the company a market capitalization of $84.64 million based upon 9.2 million shares outstanding. It also means that ZYNE has a price-to-book ratio of 2.25:1. In the past 52 weeks, shares of ZYNE have traded as low as $4.64 and as high as $43.0. Technical traders will take note that at $8.8, shares of ZYNE are trading below their 200-day MA at $9.46 and above their 50-day MA at $7.83." ENDE Zitat

Source:marijuanaindex.com/industry-news-item/?newsId=8066544143041055

Quelle/Chart:stockcharts.com/h-sc/ui?s=ZYNE

Zitat:" Sept. 06, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that it has initiated a Phase 2 clinical trial, STOP (Synthetic Transdermal Cannabidiol for the Treatment of Knee Pain due to Osteoarthritis (OA)), of ZYN002 cannabidiol (CBD) gel. ZYN002 CBD gel is the first and only patent-protected, synthetic CBD that is formulated as a permeation-enhanced gel for transdermal delivery.....“In the US, there are approximately 31 million people who suffer from osteoarthritis, many of whom are not receiving adequate relief from current therapies,” said Armando Anido, Chairman and Chief Executive Officer of Zynerba. “In preclinical models, cannabidiol has demonstrated the ability to significantly reduce pain and inflammation associated with OA. ZYN002 may offer an effective treatment alternative to NSAIDs and narcotic opioids with an improved safety profile.”The STOP clinical trial is a Phase 2 multi-center, double-blind, placebo-controlled, multi-dose clinical trial designed to evaluate the efficacy and safety of ZYN002 in patients with knee pain due to OA. Up to 300 patients will be enrolled in the clinical trial and will be followed for two weeks during a baseline phase, which includes a one-week washout period. " ENDE Zitat

Source:www.otcmarkets.com/stock/ZYNE/news

Zitat:"On Dec. 14, 2016, the United States Drug Enforcement Administration announced a new rule that makes hemp-based cannabidiol a federally illegal substance. Under the new rules, liquid extracts derived from plants of the cannabis genus that contain one or more cannabinoids are now considered a schedule I substance.....Introduced by DEA chief Chuck Rosenberg under the auspices of allowing “DEA and DEA-registered entities to track quantities of this material separately from quantities of marihuana,” the new rule has many advocates crying foul over its overly broad interpretation.....
“What DEA Administrator Rosenberg seems to be saying with this clarification is: You may be able to grow hemp. But if you try to extract CBD oil from it, the DEA considers that a federal crime,” ENDE Zitat
Source:mjinews.com/dea-issues-new-rule-to-ban-cannabidiol/

Zitat:"Zynerba Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares...............2017-02-09 07:35 ET - News Release........Feb. 09, 2017- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the underwriters of its previously announced public offering of 2.8 million shares of its common stock have exercised in full their option to purchase an additional 420,000 shares of common stock at the public offering price of $18.00 per share, l...........With the exercise of the underwriters' option, gross proceeds to Zynerba from the offering are expected to be approximately $58 million, before deducting underwriting discounts and commissions and other offering expenses payable by Zynerba. The closing of the option exercise is expected to occur on February 13, 2017, subject to customary closing conditions.... "Ende Zitat
Source:www.stockwatch.com/News/...170209&symbol=ZYNE&region=U
zynerba.com/...nnounces-proposed-public-offering-common-stock/

Solvay / Solvay Pharmaceuticals B.V., owns 17 patents
Jenrin Discovery, Inc., privately-held US , owns 9 US patents + 3 pending
Cara Therapeutics Inc. (NASDAQ: CARA) owns 9 US patents
GW Pharmaceuticals Limited (NASDAQ: GWPH), owns 8 issued patents + 22 pending
Full Spectrum Laboratories Ltd, subsidiary of Teewinot Life Sciences Corporation, owns 5 US patents + 5 pending
Insys Therapeutics, Inc. (NASDAQ: INSY) , owns 4 US patents + 4 pending
Arena Pharmaceuticals Inc. (NASDAQ: ARNA)owns 1 US patent + 2 pending
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) owns 1 US patents + 1 pending
Axim Biotechnologies, Inc. (OTCMKTS: AXIM) owns 5 pending, published US patent applications
Echo Pharmaceuticals B.V., privately-held company, owns 4 pending, published  applications
Corbus Pharamaceuticals, Inc. (NASDAQ: CRBP) owns 3 pending patent applications
Biotech Institute, LLC owns 3 pending, published US patent applications
Afgin Pharma, LLC owns 3 pending, published US patent applications
United Cannabis Corp. (OTC: CNAB) owns 2 pending, published US patent application
AbbVie, Inc. owns 35 US patents + 2 pending, published US patent applications
Bristol-Myers Squibb owns 21 US patents
Sanofi-Aventis  owns 9
Merck & Co. Inc. owns  3 US patents


patentvue.com/2017/02/01/...anies-are-rushing-to-file-patents/

patentvue.com/2017/02/01/...anies-are-rushing-to-file-patents/

Have zurzeit knapp 1000 Stück gekauft. Schauen wohin dir reise geht.  

Zitat:"Phase 2 data misses on primary endpoint and all other endpoints in the study

ZYN002 missing

... (automatisch gekürzt) ...

https://seekingalpha.com/article/...-indicate-major-short-opportunity

www.finanzen.net/analyse/...verweight-Cantor_Fitzgerald_623343

www.nasdaq.com/de/symbol/zyne/real-time

Von über 3 Mio und ein Plus von 7%zum Ende desTages.Habe mal einen Fuß in die Tür gestellt.Bei einen Kursrückgang im Bereich von 5,-$Dollar würde ich noch einige einsammeln .

momentan ohne News

seekingalpha.com/article/4253206-zynerba-rockets-forward

www.fool.com/investing/2019/04/30/...ck-is-jumping-today.aspx

www.analystratings.com/articles/...ne-still-has-room-to-grow/

• neues 52 Wochen-Hoch
  

www.proactiveinvestors.com/companies/news/...-gel-219890.html

Boden endlich gefunden?

www.zacks.com/stock/news/784807/...-zyne-this-earnings-season

www.proactiveinvestors.com/companies/news/...rome-914656.html

Zygel™ verfehlt primären Endpunkt und 3 sekundäre Endpunkte

zynerba.com/...-trial-of-zygel-cbd-gel-in-fragile-x-syndrome/

seekingalpha.com/news/...ynerbas-zygel-flunks-fragile-x-study

Regulatorisches Update zu Zygel™ beim Fragile X Syndrom (FXS)

Klinisch traue ich Zynerba´s CBD-Produktkandidat nicht viel zu, nachdem er in den letzten Jahren in vier Studien nicht bestehen konnte. Ich empfehle jedem sich folgenden Artikel durchzulesen und sich ggf. zu übersetzen um über die Risiken informiert zu sein.

endpts.com/...ther-phii-trial-all-but-ending-fragile-x-hopes/

Auf Grund der prognostizierten, relativ langen Cashreichweite bis Anfang 2023 würde ich es jedoch nicht ausschliessen, dass die Aktie von Zynerba in Richtung 6$ und drüber steigen könnte zumindest kurzfristig. Watchlist.

ir.zynerba.com/news-releases/...ides-regulatory-update-zygeltm

www.analystratings.com/articles/...ng-from-canaccord-genuity/

www.nasdaq.com/de/market-activity/stocks/zyne/real-time